IGF-1 LR3 1mg
IGF-1 LR3 1mg
IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding protein.
|
Vial Size
|
Dose Range
|
Schedule
|
Primary Goal
|
|---|---|---|---|
| 1mg vial | 20 to 50 mcg daily with gradual titration; conservative protocols remain at or under 50 mcg/day. | Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods. | Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability. |
Reconstitution Summary
Storage Summary
Reconstitution Steps
- Draw 1 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming; do not shake.
- Gently swirl or roll until the lyophilized powder dissolves completely into a clear solution.
- Label the vial with reconstitution date and refrigerate at 2 to 8 °C, protected from light.
- Use within 30 days of reconstitution; for longer storage, prepare aliquots and freeze at -20 °C for up to 3 to 6 months. At 1 mg/mL, 1 unit = 0.01 mL » 10 mcg on a U-100 insulin syringe.
How It Works
IGF-1 LR3 is a synthetic analog of human insulin-like growth factor-1 engineered with an N-terminal extension (13 amino acids) and a glutamic acid substitution at position 3, resulting in significantly reduced binding affinity to IGF binding proteins. This modification extends the peptide’s half-life from minutes (native IGF-1) to several hours and enhances systemic bioavailability. The extended circulation time allows for once-daily administration protocols in research settings. Unlike native IGF-1, which requires frequent dosing, IGF-1 LR3 maintains more stable plasma levels throughout the day. The peptide exhibits anabolic and metabolic activities through IGF-1 receptor binding, though it has never been approved for therapeutic human use and remains confined to research applications. The insulin-like properties necessitate careful attention to blood glucose management, particularly during initial dosing and titration phases.
Benefits & Side Effects
- Enhanced anabolic signaling and protein synthesis in target tissues.
- Extended bioavailability compared to native IGF-1 due to reduced binding protein interaction.
- Metabolic effects through IGF-1 receptor pathways.
- Hypoglycemia risk: The most significant concern with IGF-1 LR3 is its insulin-like effect on blood
- glucose; symptoms may include shakiness, confusion, sweating, or dizziness. Always administer with food and monitor for glucose-related symptoms.
- No FDA approval: IGF-1 LR3 has never received regulatory approval for human therapeutic use and is restricted to research applications.
- Injection site reactions: Mild local irritation, redness, or discomfort may occur.
Dose-dependent effects: Safety concerns increase substantially at doses exceeding 50 to 60 mcg/day;
conservative dosing strongly recommended. - Receptor desensitization: Continuous use beyond 6 to 8 weeks may lead to diminished response;
cycling protocols (8 on / 4 to 8 off) are commonly employed.
References & Scientific Literature
- Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports (Biomolecules / MDPI).
- Insulin-like growth factor 1 (IGF-1) and long chain IGF (LR3IGF-1): Medical information (Dopinglinkki / FINCIS).
- Detection of LongR3-IGF-I, Des(1-3)-IGF-I, and R3-IGF-I for anti-doping purposes (Drug Testing and Analysis).
- Mecasermin (Subcutaneous): proper use, dosing, and hypoglycemia management (Mayo Clinic / Drugs.com). IGF-1 LR3 (1 mg vial) Once-daily subcutaneous protocol for long-acting IGF-1 analog anabolic and metabolic research. IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified analog of human IGF-1 with significantly extended half-life, studied for its anabolic and metabolic effects. This synthetic variant exhibits reduced binding to IGF binding proteins, allowing enhanced bioavailability and systemic activity. This educational protocol presents a once-daily subcutaneous approach with conservative titration for research applications. Protocol Overview Concise summary of the regimen. Goal: Support anabolic processes and metabolic function through enhanced IGF-1 activity with extended bioavailability. Schedule: Daily subcutaneous injections for 8 weeks (standard cycle); may extend to 12 weeks with appropriate off-periods. Dose Range: 20 to 50 mcg daily with gradual titration; conservative protocols remain at or under 50 mcg/day. Reconstitution: 1 mL per 1 mg vial (1 mg/mL or 1000 mcg/mL). Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze-thaw cycles. Cycling: Common approach is 8 weeks on, 4 to 8 weeks off to prevent receptor desensitization. Dosing & Reconstitution Guide Standard / gradual approach (1 mL = 1 mg/mL). WEEK DAILY DOSE UNITS PER INJECTION Weeks 1 to 2 20 mcg 2 units (0.02 mL) Weeks 3 to 4 40 mcg 4 units (0.04 mL) Weeks 5 to 8 50 mcg 5 units (0.05 mL) Frequency: Inject once daily subcutaneously, typically in the morning or post-workout with food intake to mitigate insulin-like effects on blood glucose. For 10 unit (0.10 mL) or smaller administrations, consider 30- or 50-unit insulin syringes for improved readability. Reconstitution Steps